NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact ...

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies ...

Medtronic plc MDT is scheduled to report second-quarter fiscal 2025 results on Nov. 19, before the opening bell. In the last reported quarter, the company’s adjusted earnings of $1.23 exceeded the ...

The "Plaque Modification Devices - Market Insights, Competitive Landscape, Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.The plaque modification devices market was valued ...

The global balloon catheter market is set to experience substantial growth over the next decade, with a projected compound annual growth rate (CAGR) of 4.3% from 2023 to 2033, according to a new ...

The diversion of blood flow through arterialization of the deep veins in the foot holds up well at 2 years as a therapy for ...

Natural products are small molecules produced naturally by any organism including primary and secondary metabolites. They include very small molecules, such as urea, and complex structures ...

The HEMASHIELD grafts are the most used, most studied vascular products available in the market today. More than 2 million HEMASHIELD grafts have been implanted worldwide, demonstrating clinical ...

Trusted for more than 20 years, HEMASHIELD grafts are the most used, most studied vascular products available in the market today. More than 2 million HEMASHIELD grafts have been implanted ...

In 2003, Abbott acquired JOMED's coronary and peripheral ... nutrition products, was also acquired. In 2006, Abbott acquired Guidant, a leader in coronary and vascular products, and Kos ...